News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

U.S. Insulin Prices Rise as Sanofi (France) (SAN.PA), Novo Nordisk A/S (NVO) Await Rivals



8/16/2013 7:25:30 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Sanofi (SAN) raised the U.S. price of its Lantus insulin for a second time this year and Novo Nordisk A/S (NOVOB) may follow suit before an onslaught of generics increases competition in the $35 billion diabetes market. Sanofi raised the U.S. wholesale price of its Lantus vials by almost 15 percent to $16.64 per milliliter and of its Lantus Solostar injection pens by almost 10 percent to $18.38 per milliliter, Jack Cox, a spokesman for Paris-based Sanofi, said in an e-mail. Those increases followed a 10 percent price increase in April for both versions of Lantus, the world’s best-selling diabetes treatment.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES